#ASH21: The Jay Brad­ner in­ter­view: 'We're work­ing up a good­ly num­ber of deal­s'

John Car­roll: Well, hel­lo every­body. This is John Car­roll. I’m the ed­i­tor of End­points News, the ed­i­tor and founder of End­points News. I’m here with Jay Brad­ner, the pres­i­dent of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search. Jay, we’re go­ing to be talk­ing about ASH in just a sec­ond, but you’ve just re­cent­ly cel­e­brat­ed your sixth an­niver­sary as pres­i­dent of NI­BR. And I’m cu­ri­ous, it’s such a sig­nif­i­cant amount of time for any­body to spend in one ca­reer phase. And look­ing back over the last six years, is every­thing fun­da­men­tal­ly dif­fer­ent about the re­search process and the trans­la­tion­al are­na that you’re in?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER